Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $59.12, representing a +1.23% change from its previous close.
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Hims & Hers Health: Bumpy Ride Will End
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scrutiny, but this is industry-wide and not unique to the company. The platform is rapidly growing subscribers, launching new offerings, and targeting large under-penetrated markets domestically and internationally in a path to hitting a $6.5B 2030 sales target.
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers: The Next Chapter For Investors
Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a brand moat and delivers 76% gross margins.
Hims & Hers Health: At The Intersection Of Secular Megatrends
Hims & Hers Health, Inc. remains a Strong Buy as it is well-positioned to capitalize on secular wellness and digital health trends favored by younger generations. The company boasts stellar fundamentals, with 72.6% year-over-year revenue growth and strong EBITDA expansion, indicating robust profit potential. HIMS stock's valuation is attractive: forward P/E and P/S ratios suggest a 26% upside by the end of FY2026, supported by aggressive revenue and EPS growth forecasts.
Hims & Hers Health: Still Undervalued
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short interest remains high, but a squeeze is unlikely; technicals show strong support at $41, signaling a favorable buy zone.
Hims & Hers: The Dominant Health Platform Of The Future
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confirm rapid scaling, with 73% YoY revenue growth, high retention, SaaS-like payback, and reaffirmed guidance despite headline noise and regulatory shifts. The weight loss strategy is diversified beyond compounded GLP-1s, supporting resilient ARPU and engagement, while international expansion and lab integration add new growth levers.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets
Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making this an area of interest for those looking into the next potential upswing in their portfolios. However, for those who are okay with individual stock picking and taking on a bit more risk, there is one narrative to follow in the coming months.
Here's How I Am Buying Hims & Hers At $37 Or Earning 4.2% Monthly Instead
Hims & Hers is undervalued, rapidly scaling a vertically integrated, consumer-focused healthcare platform with 73% YoY revenue growth and strong EBITDA margins. Market fears over GLP-1 regulatory changes are overblown; Hims' personalized care model drives superior retention, recurring revenue, and positions them for future weight loss drug launches. Valuation appears high, but relative to hypergrowth, expanding margins, and HIMS offers significant long-term upside even in bear case scenarios.
